Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2018 August;66(4) > Minerva Cardioangiologica 2018 August;66(4):422-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  STEMI: CURRENT KNOWLEDGE AND FUTURE PERSPECTIVES 

Minerva Cardioangiologica 2018 August;66(4):422-8

DOI: 10.23736/S0026-4725.18.04640-6

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Antiplatelet therapy in STEMI undergoing primary PCI: when, which one and how long

Giorgio BARALIS, Roberta ROSSINI, Giuseppe MUSUMECI

Unit of Cardiology, Department of Emergencies and Critical Areas, Santa Croce e Carle Hospital, Cuneo, Italy


PDF


Reperfusion therapy for patients presenting with an acute ST-segment elevation myocardial infarction (STEMI) involves primary percutaneous coronary intervention (PPCI) and concomitant dual antiplatelet therapy (DAPT) with combination of a P2Y12 inhibitor and acetylsalicylic acid (ASA). Decision regarding DAPT can be challenging clinically in the modern era with the evolution of newer stents, more potent antiplatelet agents and novel anticoagulant drugs in addition to an older patient population with multiple comorbidities. This review outlines the currently available antiplatelet treatments, and their place within the therapeutic timeline of a patient presenting with STEMI.


KEY WORDS: Aspirin - Stents - Anticoagulants

top of page